Coach. Teacher. Cancer survivor. And Storyteller. Bob Ashworth cherishing latest chapter.
Bob Ashworth coached football at Lawrence Central and Broad Ripple. Now 'Papa Ash' is helping son John on the Hamilton ...
Future Market Insights5h
Global Enteral Formula Market to Reach USD 15.6 Billion by 2034, Expanding at a 6.9% CAGR | Future Market Insights, Inc.
The global Enteral Formula industry has an estimated market valuation of USD 8.0 billion by 2024 and is projected to grow at ...
F.D.A. Approves Ozempic to Treat Kidney Disease
The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have ...
FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients
Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...
dermatologyadvisor4h
Cancer Statistics for 2025
The ACS has released cancer statistics for 2025 suggesting that more than 2 million new cases of cancer will be diagnosed in the US this year.
Endocrinology Advisor17h
Select GLP-1 Receptor Agonists Reduce Risk of CKD Progression, ESKD, and MACE
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...
Study highlights new target and potential therapy for treatment-resistant cancers
University of Kentucky Markey Cancer Center researchers have discovered a promising new way to combat therapy-resistant ...
Healio22h
FDA approves new indication for Ozempic to lower kidney risks in type 2 diabetes, CKD
The FDA has approved a new indication for semaglutide to lower the risk for worsening kidney disease, kidney failure and cardiovascular death among adults with type 2 diabetes and chronic kidney ...